More on Edwards Lifesciences (EW): Q3 beats on a per share basis but comes up short on revenue...

|About: Edwards Lifesciences Corp (EW)|By:, SA News Editor

More on Edwards Lifesciences (EW): Q3 beats on a per share basis but comes up short on revenue as sales growth in its transcatheter heart valves ran below expectations. Looking forward, the company says it expects a strong close to the year with today's FDA approval of expanded indications for SAPIEN, which will allow it to serve many more patients.